Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NPC Value Conference Sparks Dialogue to Define, Understand Value in Health Care

September 30, 2016

How do we measure the value of a medical intervention, its benefits to patients, and the associated costs to patients, payers and society as a whole? Hundreds of stakeholders gathered in-person and online to tackle this question at the National Pharmaceutical Council’s Assessing Value: Promise & Pitfalls conference on September 29.

During presentations and panel discussions, patient organizations, payers, providers and biopharmaceutical manufacturers shared their views about existing value assessment frameworks, what steps need to be taken to improve these frameworks, and how to ensure that patients are engaged throughout the development and assessment processes.

NPC President Dan Leonard kicked off the conference by highlighting the importance of bringing stakeholders together for this conversation:

“With so many new life-saving and life-improving treatments for cancer or medicines to treat rare or chronic conditions—it is more important now than ever to be able to capture and communicate the value of these ground-breaking medicines.

“Moving in parallel to these scientific breakthroughs is a massive health care system transition—one shifting from a focus on paying for the volume of health services … to one paying for the value of health benefits accrued to the patient. In this changing environment, how do we measure value? And how can we make sure that patients have a full voice in how value is measured?

“There’s no one right answer.

“A number of organizations have developed value assessment frameworks intended to answer these questions, but the field is relatively young and still evolving. These early value assessments could have a tremendous impact on patient treatment decisions, as well as on coverage and reimbursement decisions. So it’s important for us to bring all health care stakeholders together to help shape the development of value assessment going forward.

“If we get it right, value assessments can be valuable and useful tools. But if we get it wrong, these tools could be used to limit patient’s ability to get the new or innovative therapies they need.”

To date, organizations such as the Institute for Clinical and Economic Review, National Comprehensive Cancer Network, Drug Abacus, American College of Cardiology-American Heart Association and the American Society of Clinical Oncology have developed frameworks, which were designed as decision-making aids with different end-users in mind.

As Leonard said:

“That’s an important point to note. One framework cannot meet the needs of all stakeholders. Different frameworks will be needed to answer different questions.

“There is much more work that needs to be done before these frameworks are ready for widespread adoption and use.”

To assist in guiding the field, earlier this year NPC developed and disseminated Guiding Practices for Patient-Centered Value Assessment. The guiding practices set forth some basic guideposts to help developers, such as making sure input from patients and other stakeholders is fully incorporated, using established methods and transparent models and assumptions, using sound, high-quality evidence, and including a broad array of factors that matter to patients and society, among other practices.

Although the conference itself was just one day, the dialogue – and NPC’s engagement with stakeholders—will continue, particularly as the field of value assessment evolves and matures. NPC is proud to play a constructive role in this ongoing conversation.

View the archived video and look for additional conference highlights and conversations on this blog during the next few weeks. To learn more about value framework assessments, please visit NPC’s Guiding Practices for Patient-Centered Value Assessment and Current Landscape: Value Assessment Frameworks.

Blog Post

Putting Patients First® in the Value Equation: An Interview With the National Health Council’s Dr. Eleanor Perfetto

National Pharmaceutical Council President Dan Leonard caught up this week with Eleanor Perfetto, PhD, MS, Senior Vice President of Strategic...
Commentary and Testimony Page

Chain Drug Review – Commentary: "Considering Value in Health Care"

This commentary was originally published in the July 25, 2016, issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Press Release

National Pharmaceutical Council to Host Conference on Measuring Health Care Value and Impact on Patient Care

(Washington, DC, September 15, 2016)—The National Pharmaceutical Council (NPC) will bring together health care stakeholders on September 29 for a...
Commentary and Testimony Page

NPC Submits Comments to Institute for Clinical and Economic Review on Its Value Framework

September 12, 2016Steven D. Pearson, MD, MSc, FRCP President Institute for Clinical and Economic Review One State Street, Suite 1050 Boston, MA 02109...
Press Release

National Pharmaceutical Council to Host Conference on Measuring Health Care Value and Impact on Patient Care

(Washington, DC, September 15, 2016)—The National Pharmaceutical Council (NPC) will bring together health care stakeholders on September 29 for a...
Press Release

National Pharmaceutical Council Remains Engaged With the Institute for Clinical and Economic Review, Continuing Constructive Dialogue to Improve Value Assessment Frameworks

(Washington, DC, September 8, 2016)—The National Pharmaceutical Council (NPC) Board of Directors has agreed to renew the health policy research...
Press Release

NPC Takes Issue With ICER's Mischaracterization of Funding Sources

The National Pharmaceutical Council (NPC) takes exception to the Institute for Clinical and Economic Review’s (ICER) continued portrayal of us as an...
Commentary and Testimony Page

Chain Drug Review – Commentary: "Considering Value in Health Care"

This commentary was originally published in the July 25, 2016, issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Submits Comments to Institute for Clinical and Economic Review on Its Value Framework

September 12, 2016Steven D. Pearson, MD, MSc, FRCP President Institute for Clinical and Economic Review One State Street, Suite 1050 Boston, MA 02109...
Commentary and Testimony Page

Thinking Differently About How We Assess Health Value

Health care stakeholders remain divided over how the value of health care treatments—especially medicines—should be assessed, and whether existing...
Blog Post

Putting Patients First® in the Value Equation: An Interview With the National Health Council’s Dr. Eleanor Perfetto

National Pharmaceutical Council President Dan Leonard caught up this week with Eleanor Perfetto, PhD, MS, Senior Vice President of Strategic...
Blog Post

NPC Submits Comments to Institute for Clinical and Economic Review on Its Value Assessment Framework

The National Pharmaceutical Council (NPC) today submitted comments to the Institute for Clinical and Economic Review (ICER) about ways to improve its...
Blog Post

Moving Value Frameworks from Fledgling to Functional

Defining value in health care – especially as our health system shifts its focus from rewarding the volume of services provided to rewarding the...
Blog Post

CER Tweets of the Week: AHCJ CER Fellowships Announced; Latest Issue of JCER Published (August 8-12)

Last week, comparative effectiveness research stakeholders tweeted about the announcement of this year’s Association of Health Care Journalists CER...
Current Landscape: Value Assessment Frameworks

Current Landscape: Value Assessment Frameworks

This paper builds on Neumann and Cohen's informative comparison of value assessment frameworks...